Search results: found 7 materials
![Rostec has Delivered 8.48 million Vaccine Doses to Russian Regions](/thumb/194x139xCUT/upload/iblock/131/1a5gr01mvza4ly7xf3x8uxw2pkag8w78.jpg)
Rostec has Delivered 8.48 million Vaccine Doses to Russian Regions
Russian medical facilities have received drug products for protection against pertussis, tetanus, diphtheria, hepatitis B, tuberculosis and rubella
![Rostec to Deliver 800,000 Measles Vaccine Doses to the Russian Regions](/thumb/194x139xCUT/upload/iblock/903/otm2r6ft6upsaqxbk3s4b1xx44ifbet3.jpg)
Rostec to Deliver 800,000 Measles Vaccine Doses to the Russian Regions
The campaign is focused on the immunization of social groups not covered by the standard vaccination procedure
![Natsimbio is Launching a New Drug for the Treatment of Immunodeficiencies](/thumb/194x139xCUT/upload/iblock/d7c/q9jfdg68xjphkfepaxopwd4g40w5187p.jpg)
Natsimbio is Launching a New Drug for the Treatment of Immunodeficiencies
BioGam drug will substitute for its foreign analogues and increase the availability and quality of therapy
![The Human Stem Cell Institute and Rostec are Developing Influenza and COVID-19 Vaccine](/thumb/194x139xCUT/upload/iblock/b3d/07xc64zqxeve84d87l9t2ass4o2vsw44.jpg)
The Human Stem Cell Institute and Rostec are Developing Influenza and COVID-19 Vaccine
Clinical study of the combination vaccine formulation is to be started in the second half of the year
![Microgen Developed Drug for ICP Treatment](/thumb/194x139xCUT/upload/iblock/d8f/d8f5e03e5cb3ab2b602454d82186763b.jpg)
Microgen Developed Drug for ICP Treatment
The first Russian made drug for cerebral palsy caused spastic ailment treatment is abreast with the oversees counterparts
![Nacimbio to Showcase Key Projects and New Development](/thumb/194x139xCUT/upload/iblock/a99/a99815acafca7899e43dd6e41f615fba.jpg)
Nacimbio to Showcase Key Projects and New Development
The pharmaceutical holding company participates in the “PharmMedProm-2017” exhibition
![Nacimbio Participated in Panel Discussions at the BIOTECHMED](/thumb/194x139xCUT/upload/iblock/371/371db7bbd040897a8b63c6e3b14324bc.jpg)
Nacimbio Participated in Panel Discussions at the BIOTECHMED
Special attention was paid to the need for transition to multicomponent prophylactic drugs